Elanco Animal Health Stock Price, News & Analysis

Elanco (NYSE: ELAN) received an FDA Emergency Use Authorization (EUA) on October 24, 2025 for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs — the first-ever EUA for NWS in dogs. The EUA follows a peer-reviewed study reporting 100% efficacy against C. hominivorax larvae within 24 hours after oral dosing at the minimum recommended level in 11 naturally infested dogs. The authorization provides a ready treatment option for veterinarians and owners as confirmed NWS cases sit under 70 miles south of the U.S.-Mexico border. Limitations include small sample size, lack of a control group, and uncertain inferential value to U.S. populations.

Elanco (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9:00 a.m. to 12:00 p.m. ET in New York City.

Senior leadership will present on strategic priorities, financial outlook, and the innovation pipeline. Advance registration is required for in-person attendance; institutional investors and analysts should contact investor@elanco.com. A live webcast, registration details, and presentation materials will be available on Elanco's Investor Events and Presentations website, and a replay will be posted after the event.

Elanco Animal Health (NYSE:ELAN) has scheduled its third quarter 2025 financial results announcement for Wednesday, November 5, 2025. The company will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly performance with investors, media, and the general public.

A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the event concludes.

Elanco Animal Health (NYSE:ELAN) announced that the FDA has approved important updates to the U.S. Zenrelia label, removing language about vaccine-induced disease risk. Zenrelia, approved in September 2024, is a once-daily oral JAK inhibitor for controlling itching and inflammation in dogs with skin allergies.

The FDA's decision came after evaluating supplemental scientific data, concluding that "the totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling." The medication has treated over half a million dogs globally, with availability in multiple markets including the EU, Great Britain, Brazil, Japan, and the United States.

The label's Boxed Warning still advises discontinuing Zenrelia for 28 days to 3 months before vaccination and withholding it for at least 28 days after vaccination due to inadequate immune response risks.

Elanco Animal Health (NYSE:ELAN) announced major milestones for two key pet health products. Credelio Quattro achieved blockbuster status with $100 million in net sales in less than eight months, becoming Elanco's fastest pet health blockbuster. The product captured 14% dollar share in broad-spectrum sales at U.S. veterinary clinics in June.

The company also announced the launch of Zenrelia, a once-daily oral JAK inhibitor for treating allergic and atopic dermatitis in dogs, in the EU and Great Britain. The product has already treated over half a million dogs globally and demonstrated non-inferiority versus Apoquel in a study of 338 dogs across 25 sites.

Elanco (NYSE:ELAN) has partnered with Splenda® and HATCH to launch Nutrition Secure Indianapolis, a comprehensive nutrition and wellness initiative targeting 250 Indianapolis families. The 12-month program combines weekly nutritious food deliveries with educational support to address food insecurity and promote better health outcomes.

The evidence-based initiative features weekly food boxes containing protein, produce, and low-sugar alternatives, alongside in-person education on healthy cooking and meal planning. The program is designed to be measurable and scalable, with built-in research components to assess its community impact and potential for expansion to other locations.

Elanco Animal Health (NYSE:ELAN) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference, scheduled for September 8-9, 2025. The company's leadership, including President and CEO Jeff Simmons and EVP and CFO Bob VanHimbergen, will engage in a fireside chat on September 9 at 8:30 a.m. ET.

Investors can access a live audio webcast through the "Events and Presentations" section of Elanco's investor website, with a replay available for a limited time after the event.

Elanco Animal Health (NYSE:ELAN) reported strong Q2 2025 results with revenue of $1.241 billion, up 5% year-over-year and 8% organic constant currency growth. The company achieved $11 million in reported net income and $131 million in adjusted net income.

Key performance metrics include Adjusted EBITDA of $238 million with a 19.2% margin, and EPS of $0.02 (reported) and $0.26 (adjusted). The company's net leverage ratio improved to 4.0x.

Based on strong performance, Elanco raised its 2025 guidance, now expecting revenue of $4.57-4.62 billion, increased innovation revenue target by $60 million to $720-800 million, and improved year-end net leverage ratio target to 3.8x-4.1x. The company plans to increase gross debt paydown to $500-550 million in 2025.

Elanco Animal Health (NYSE:ELAN) has received European Commission approval for Zenrelia™ (ilunocitinib), a once-daily oral JAK inhibitor for treating itching associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and older.

The approval follows a successful head-to-head study against market incumbent Apoquel, involving 338 dogs across 25 study sites in four countries, demonstrating Zenrelia's non-inferiority. The product is already available in Brazil, Canada, Japan, and the United States, with launch in EU markets expected before the end of Q3 2025.